|
United States Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The United States Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for the United States .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the American pharmaceutical and healthcare industry.
Competitive intelligence, American pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the American market.
The United States Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s United States Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the American pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on the United States to test other views – a key input for successful budgeting and strategic business planning in the American pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the American Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in the United States .
- Exploit The Latest Competitive American Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in the United States .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
United States Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - CONTENTS |
Executive Summary |
| US Pharmaceuticals And Healthcare Industry SWOT |
| United States Political SWOT |
| United States Economic SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings |
| Limits to Potential Returns |
| Risks to Realisation of Returns |
Chapter - US - Market Summary |
| Regulatory Regime |
| Pharmaceutical Advertising |
| Table: Examples Of Off-Label Drug Use |
| Recent Regulatory Developments |
| International Regulatory Collaboration |
| Biosimilars |
| Intellectual Property Developments |
| Pricing And Reimbursement Environment |
| Price Rises |
| Part D |
| Other Reimbursement Issues |
Chapter - Industry Developments |
| Epidemiology |
| Table: Vaccine-Preventable Diseases |
| Healthcare Sector |
| Universal Healthcare |
| Healthcare Expenditure |
| E-Health |
| Pharmaceutical Industry |
| Drug Distribution Sector |
| Table: Channel Distribution By US Sales (US$bn) |
| Table: Channel Distribution By US Dispensed Prescription (mn) |
| Pharmacy Retail Sector |
| Table: Leading 10 Products By US Dispensed Prescriptions (mn) |
| Cross-Border Pharmacy Retail |
| Research and Development Sector |
| Clinical Trials Sector |
| Biotechnology Sector |
| Table: Biotechnology Medicines Under Development, 2006 |
| Medical Device Market |
| Medical Device Manufacturing |
| Table: 10 Leading Corporations By US Sales (US$bn) |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: US - Pharmaceuticals And Healthcare Sector, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Key Growth Factors – Industry |
| Table: US - Healthcare Sector Indicators, Historical Data And Forecasts |
| Table: United States – Economic Activity |
| Prescription Market Forecast |
| Table: US – Prescription Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Patented Market Forecast |
| Seclected Results From Harris Generics Poll |
| Table: US - Patented Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: US – Generics Market Indicators, Historical Data And Forecasts |
| OTC Market Forecast |
| Table: US – OTC Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Export/Import Forecasts |
| Table: US - Pharmaceuticals Trade, Historical Data And Forecasts (US$mn) |
| Medical Device Market Forecasts |
| Other Healthcare Data |
| Table: US – Other Healthcare Indicators, Historical Data And Forecasts |
| Table: US – Pharmaceuticals Sector Indicators, Historical Data And Forecasts |
Chapter - Competitive Landscape |
| Table: Channel Distribution By US Sales (US$bn) |
| Table: Leading 10 Therapeutic Classes By US Dispensed Prescriptions (mn) |
| Table: 10 Leading Corporations By Total US Dispensed Prescriptions (mn) |
| Table: 10 Leading Corporations By US Sales (US$bn) |
| Table: Leading 10 Products By US Sales (US$bn) |
| Table: Leading 10 Products By US Dispensed Prescriptions (mn) |
Chapter - Company Profiles Company Profiles |
| Pfizer |
| GlaxoSmithKline (GSK) |
| Novartis |
| Merck & Co |
| Eli Lilly |
| Bristol-Myers Squibb (BMS) |
| Amgen |
| Genentech |
Chapter - Country Snapshot: US Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 (US$) |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
United States Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The US pharmaceutical market is the largest in the world and, accordingly, it has the world’s highest per capita drug spending – currently US$1,031. This figure is, however, forecast to fall to just US$950 by 2013, changing at a compound annual growth rate (CAGR) of -1.62%. The total market, valued at US$313.6bn in 2008, will also experience a contraction (of CAGR -0.66%) to 2013, when it will be worth around US$303.4bn at consumer prices. While medicines are considered to be essential items, and are widely used across the country, certain factors will take their toll on the values over the coming years: the economic recession, falling prescription numbers, the patent cliff, and the encouragement of the use of generics.
The pharmaceutical landscape in the US is expected to become, on the one hand, more challenging for research-based companies over the coming years, following the inauguration of the new administration led by President Barack Obama. While his plans include a programme for bringing some 50mn currently uninsured people into the healthcare system, high medicines prices may be targeted. A more damaging development is the debated bill that would prohibit patent-holders to use authorised generics to combat competition. On the other hand, the January 2009 reversal of the federal funding restrictions placed on stem cell research and therapies – which were in place in the US since 2001 – indicates the new administration’s willingness to encourage innovation.
In terms of major industry news, the leading global drugmaker, US-based Pfizer, is to acquire its compatriot Wyeth. This will be the largest single consiladative deal the pharmaceutical industry since 2000, and also one of the most controversial, given large-scale job cuts in the current economic climate. The mega-merger, indicative of the more difficult operating environment that is occurring in the run-up to the 2011 patent cliff (when many patents on drugs are set to expire), will see two of the top 10 pharmaceutical companies by sales combine to create 'the world's premier biopharmaceutical company'. BMI considers the main goals of the merger to be therapeutic and product platform diversification, given Wyeth’s considerable biologics portfolio, thus reducing reliance on individual products. In the meantime, approximately one-third of the small biotech pharmaceutical companies in the US are expected to discontinue their operations in 2009 due to the slowdown in the market, as forecast by Esperion Therapeutics' Chief Executive Officer (CEO).
Indeed, we are forecasting a 2% contraction in the US economy in 2009, as fixed investment and consumer activity retrench heavily. The 2010 recovery will be modest, with growth of just 0.8%, as deflation/disinflation for both prices and assets remains our core scenario.The one driver of US growth over the past few quarters has been net exports, driven by a reduction in imports and by the fact that the weak dollar has been improving export competitiveness.
|
United States Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |